The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
Blood will be collected and sent for testing using the Quest AD-Detect blood test
Cumberland Medical Center
Crossville, Tennessee, United States
RECRUITINGRoane Medical Center
Harriman, Tennessee, United States
RECRUITINGFort Sanders Regional Medical Center
Knoxville, Tennessee, United States
RECRUITINGFort Loudon Medical Center
Lenoir City, Tennessee, United States
RECRUITINGMethodist Medical Center
Oak Ridge, Tennessee, United States
RECRUITINGLeConte Medical Center
Sevierville, Tennessee, United States
RECRUITINGTo show the percentage of patients (21 patients in the study) who presented with a cognitive diagnosis (including but not limited to delirium, encephalopathy, etc.) that have a positive biomarker for Alzheimer's dementia
A Six month follow up with the Neurology clinic to discuss the results of Quest AD Detect (p-tau217), those patients who are found to have a positive outcome will receive additional follow-up in the Neurology clinic (which could include the use of additional lab tests or further diagnostic testing).
Time frame: From enrollment to 6 month follow up appointment with Neurology Clinic.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.